Literature DB >> 25326400

Where and when device therapy may be useful in the management of drug-resistant hypertension.

Herbert D Aronow1, Jun Li, Sahil A Parikh.   

Abstract

Device therapy for the treatment of uncontrolled and resistant hypertension has evolved significantly over the past several decades. Both renal artery disease and sympathetic hyperactivity have been linked to resistant hypertension. This manuscript will review the current evidence base supporting device therapy (e.g., renal artery revascularization, sympathetic nervous system modulation) for resistant hypertension.

Entities:  

Mesh：

Year:  2014        PMID： 25326400     DOI： 10.1007/s11886-014-0546-8

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  81 in total

1.  Guidelines for the reporting of renal artery revascularization in clinical trials. American Heart Association.

Authors:  John H Rundback; David Sacks; K Craig Kent; Christopher Cooper; Daniel Jones; Timothy Murphy; Kenneth Rosenfield; Christopher White; Michael Bettmann; Stanley Cortell; Jules Puschett; Dan Clair; Patricia Cole
Journal:  Circulation       Date:  2002-09-17       Impact factor: 29.690

2.  Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.

Authors:  George L Bakris; Mitra K Nadim; Hermann Haller; Eric G Lovett; Jill E Schafer; John D Bisognano
Journal:  J Am Soc Hypertens       Date:  2012-02-15

Review 3.  Renovascular hypertension and ischemic nephropathy.

Authors:  Vesna D Garovic; Stephen C Textor
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

4.  Observations on sixty patients with hypertension successfully treated by splanchnicectomy.

Authors:  S W HOOBLER; J T MANNING; W G PAINE; P O HELCHER; S G McCLELLAN; H RENFERT; E A KAHN; M M PEET
Journal:  Med Bull (Ann Arbor)       Date:  1950-12

5.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial.

Authors:  John D Bisognano; George Bakris; Mitra K Nadim; Luis Sanchez; Abraham A Kroon; Jill Schafer; Peter W de Leeuw; Domenic A Sica
Journal:  J Am Coll Cardiol       Date:  2011-08-09       Impact factor: 24.094

6.  Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: a meta-analysis of randomized controlled trials.

Authors:  Dharam J Kumbhani; Anthony A Bavry; James E Harvey; Russell de Souza; Roberto Scarpioni; Deepak L Bhatt; Samir R Kapadia
Journal:  Am Heart J       Date:  2011-03       Impact factor: 4.749

7.  Stenting of a renal artery stenosis achieves better relief of the obstructive lesion than balloon angioplasty.

Authors:  G Dorros; C Prince; L Mathiak
Journal:  Cathet Cardiovasc Diagn       Date:  1993-07

8.  Renal artery stenosis in patients with resistant hypertension.

Authors:  Marcin Protasiewicz; Jacek Kądziela; Karol Początek; Rafał Poręba; Maciej Podgórski; Arkadiusz Derkacz; Aleksander Prejbisz; Andrzej Mysiak; Andrzej Januszewicz; Adam Witkowski
Journal:  Am J Cardiol       Date:  2013-11-01       Impact factor: 2.778

9.  Effects of Renal Sympathetic Denervation on 24-hour Blood Pressure Variability.

Authors:  Christine S Zuern; Konstantinos D Rizas; Christian Eick; Cosmina Stoleriu; Lena Bunk; Petra Barthel; Bernd Balletshofer; Meinrad Gawaz; Axel Bauer
Journal:  Front Physiol       Date:  2012-05-10       Impact factor: 4.566

10.  Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.

Authors:  Stephen G Worthley; Costas P Tsioufis; Matthew I Worthley; Ajay Sinhal; Derek P Chew; Ian T Meredith; Yuvi Malaiapan; Vasilios Papademetriou
Journal:  Eur Heart J       Date:  2013-06-19       Impact factor: 29.983
View more
  1 in total

1.  Acute Sildenafil Use Reduces 24-Hour Blood Pressure Levels in Patients With Resistant Hypertension: A Placebo-Controlled, Crossover Trial.

Authors:  Arthur Santa Catharina; Rodrigo Modolo; Alessandra Mileni Versuti Ritter; Thiago Quinaglia; Rivadávio Fernandes Batista de Amorim; Heitor Moreno; Ana Paula de Faria
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-06-01       Impact factor: 3.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.